Table 1.

Patient Characteristics

		Single test n = 1398 (%)	Serial tests n = 144 (%)	p-value
Race n (%)	Caucasian	993 (71.0%)	104 (72.2%)	0.93
	Black	276 (19.7%)	28 (19.4%)
	Other	129 (9.2%)	12 (8.3%)
Median age at diagnosis (interquartile range)		63 (57–69)	61 (54–67)	0.03
Gleason at diagnosis n (%)	6–7	359 (25.7%)	39 (27.1%)	0.90
	8–10	763 (54.6%)	79 (54.9%)
	Missing	276 (19.7%)	26 (18.1%)
Median PSA at diagnosis (interquartile range)		18.25 (7.18–94.75)	25.8 (8.7–146.95)	0.09
Histology n (%)	Adeno	1241 (88.8%)	129 (89.6%)	0.26
	Neuro	10 (0.72%)	2 (1.4%)
	Mixed	2 (0.14%)	1 (0.69%)
	Missing	145 (10.4%)	12 (8.3%)
T stage at diagnosis n (%)	T1–T2	484 (34.6%)	32 (22.2%)	<0.0001
	T3–T4	322 (23.0%)	28 (19.4%)
	Tx	428 (30.6%)	73 (50.7%)
	Missing	164 (11.7%)	11 (7.6%)
N stage at diagnosis n (%)	N0	445 (31.8%)	40 (27.8%)	0.28
	N1	348 (24.9%)	45 (31.3%)
	Nx	440 (31.5%)	47 (32.6%)
	Missing	165 (11.8%)	12 (8.3%)
M stage at diagnosis n (%)	M0	469 (33.6%)	62 (43.1%)	0.10
	M1	429 (30.7%)	43 (29.9%)
	Mx	336 (24.0%)	27 (18.8%)
	Missing	164 (11.7%)	12 (8.3%)
De novo metastatic n (%)	Yes	588 (42.1%)	59 (41.0%)	0.59
	No	681 (48.7%)	76 (52.8%)
	Missing	129 (9.2%)	9 (6.3%)
Sites of first metastases n (%)	Pelvic LN	553 (39.6%)	66 (45.8%)	0.15
	Distant LN	431 (30.8%)	43 (29.9%)	0.85
	Bone	934 (66.8%)	94 (65.3%)	0.71
	Liver	78 (5.6%)	6 (4.2%)	0.57
	Lung	104 (7.4%)	8 (5.6%)	0.50
	Bladder	52 (3.7%)	3 (2.1%)	0.48
	CNS	6 (0.43%)	0 (0%)
	Other	60 (4.3%)	6 (4.2%)	1.00
Primary definitive therapy n (%)	Radical Prostatectomy	543 (38.8%)	56 (38.9%)	0.93
	Definitive Radiation	609 (43.6%)	73 (50.7%)	0.11
	Brachytherapy	57 (4.1%)	7 (4.9%)	0.66
	Cryotherapy	27 (1.9%)	0 (0%)
	None	162 (11.6%)	8 (5.6%)
Mean # of systemic treatments after the first NGS test result per patient		1.40	1.65	0.012
Systemic treatments after the first NGS test result	Total	677	178
	PARP inhibitor	70	14	0.40
	Immunotherapy	64	13	0.46
	Taxane	479	116	<0.0001
	Platinum	64	35	0.0003